Impact of Discontinuing Oxytocin in Active Labor on Neonatal Morbidity: An Open-Label, Multicenter, Randomized Trial

( Lancet . 2023;402(10417)2091–2100. doi: 10.1016/S0140-6736(23)01803-2) Oxytocin is a widely used drug worldwide, employed in either labor induction or labor augmentation. However, ambiguities persist regarding the ideal length of oxytocin delivery and its potential impact on neonatal and maternal outcomes. A previous clinical trial conducted in 2021 found a trivial rise in cesarean deliveries when oxytocin was discontinued, although this difference lacked both clinical and statistical significance. The current study sought to assess the effects of discontinuing oxytocin during the active phase of labor on neonatal morbidity and maternal complications.

Authors

Publication Details

Journal
Obstetric Anesthesia Digest
Published
2024-08-23
DOI
https://doi.org/10.1097/01.aoa.0001026588.44771.63
Primary Topic
Maternal and Perinatal Health Interventions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of Discontinuing Oxytocin in Active Labor on Neonatal Morbidity: An Open-Label, Multicenter, Randomized Trial

Paul Guerby, Éric Boudier, G Lévy, Aude Girault et al.
Obstetric Anesthesia Digest
Maternal and Perinatal Health Interventions
article

Impact of Discontinuing Oxytocin in Active Labor on Neonatal Morbidity: An Open-Label, Multicenter, Randomized Trial

Paul Guerby, Éric Boudier, G Lévy, Aude Girault, Tiphaïne Raia-Barjat, Camille Le Ray, Gilles Kayem, Diane Korb, Jessica Rousseau, Julie Carrara, Paul Berveiller, Charles Garabédian, Mona Massoud, Loı̈c Sentilhes, Raoul Desbrière, Éric Verspyck, Hélène Heckenroth, N. Winer, Élie Azria, Caroline Bohec, Julie Blanc, C. Bertholdt, G Roth
article en

Abstract

( Lancet . 2023;402(10417)2091–2100. doi: 10.1016/S0140-6736(23)01803-2) Oxytocin is a widely used drug worldwide, employed in either labor induction or labor augmentation. However, ambiguities persist regarding the ideal length of oxytocin delivery and its potential impact on neonatal and maternal outcomes. A previous clinical trial conducted in 2021 found a trivial rise in cesarean deliveries when oxytocin was discontinued, although this difference lacked both clinical and statistical significance. The current study sought to assess the effects of discontinuing oxytocin during the active phase of labor on neonatal morbidity and maternal complications.

Obstetric Anesthesia DigestVol. 44(3)
Decent work and economic growth
Openalex Percentile: Top 78%
Maternal and Perinatal Health Interventions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Impact of Discontinuing Oxytocin in Active Labor on Neonatal Morbidity: An Open-Label, Multicenter, Randomized Trial — Paul Guerby, Éric Boudier, et al. · Obstetric Anesthesia Digest (2024) | TGRS Research Map | TGRS